

**Date: 04th February, 2025**

To,
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730**Subject: Outcome of Board Meeting**

Dear Sir / Madam,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, February 04, 2025 has inter-alia, considered, adopted and approved following items of business:

1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 31st December, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder;
2. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today has ratified incorporation of a Wholly Owned Subsidiary ("WOS") with the name as Fredun Retail Private Limited as approved by the Ministry of Corporate Affairs, Government of India.

The details as required under SEBI circular no: SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure A

In furtherance to the intimation filed by the Company dated December 30, 2024; the trading window for trading in securities of the Company by insiders closed on January 01, 2025 till the end of 48 hours after the declaration of outcome of Board Meeting.

The Board Meeting commenced at 03:30 p.m. and concluded at 07:45 p.m.
Kindly oblige and take the same on your Records.

**Thanking you,
For Fredun Pharmaceuticals Limited**

**Jinkal Shah
Company Secretary and Compliance Officer
Membership No.: A40722**



R.H.Nisar & Co.
Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063
Tel no: 2686 9939, 2686 9940

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Company') for the quarter ended December 31, 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and has been reviewed by the audit committee and approved by the Company's Board of Directors at their respective meeting held on February 04, 2025, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W



RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 25103659BMOCXD8098

PLACE: MUMBAI
DATE: 04.02.2025



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2024
Rs. In Lakhs

PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
	Unaudited			Unaudited		Audited
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
1 Income from Operations						
Net Sales /IncomeFrom Operation (Net of GST)	10184.09	10689.19	8665.48	28626.86	22936.27	34657.69
2 Other Operating Income	85.58	46.16	35.34	259.24	167.61	249.49
3 Total income from operatoins (net)	10269.67	10735.35	8700.82	28886.10	23103.88	34907.18
4 Expenses						
a) Cost of Material Consumed	7265.62	6739.80	7508.03	19756.09	19085.22	28241.83
b) Cost of Material Consumed for R & D	52.25	51.23	47.57	141.16	109.17	134.19
c) Other R & D Expenses	0.00	0.00	0.00	0.00	0.00	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	(26.07)	787.11	(1206.13)	728.36	(2054.00)	(2243.65)
e) Manufacturing & Service Cost	472.72	496.17	353.48	1296.57	949.92	1361.65
f) Finance Costs	500.47	531.21	376.57	1422.92	927.84	1365.01
g) Employeess benefits expenses	584.93	358.46	297.26	1253.33	859.95	1249.98
h) Depreciation and amortisation expenses	108.92	106.32	98.58	319.96	283.96	379.59
i) Other Expenses	597.42	907.45	648.99	1944.80	1380.48	2273.39
Total expenses	9556.26	9977.75	8124.35	26863.19	21542.54	32761.99
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	713.41	757.60	576.47	2022.91	1561.34	2145.19
6 Exceptional items / Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	713.41	757.60	576.47	2022.91	1561.34	2145.19
8 Tax Expenses	180.15	330.27	154.16	649.33	505.24	582.85
9 Profit/(Loss) from continuing operations	533.26	427.33	422.31	1373.58	1056.10	1562.34
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Profit/ (Loss) for the period	533.26	427.33	422.31	1373.58	1056.10	1562.34
14 Other comprehensive Income						
A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Re measurement of post - employment benefit obligations	0.00	0.00	0.00	0.00	0.00	7.04
C (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Comprehensive Income for the year	533.26	427.33	422.31	1373.58	1056.10	1569.38
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	472.17	472.17	469.92	472.17	469.92	469.92
16 Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	11677.2
17 Earning per Share (EPS) (before & after extra ordinary items)						
- Basic/ Diluted Earning Per Share (Rs.)	11.29	9.05	8.99	29.09	22.47	33.32
A 1) Public Shareholding						
Number of shares	2411277	2411277	2389277	2411277	2389277	2388777
Percentage of shareholding	51.07%	51.07%	50.84%	51.07%	50.84%	50.84%
2) Promoters and promotor group shareholding						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	2310385	2310385	2309885	2310385	2309885	2310385
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of total share capital of the Company)	48.93%	48.93%	49.16%	48.93%	49.16%	49.16%

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

Notes

- 1 The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 04, 2025. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above unaudited financial results for the quarter ended December 31, 2024 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Rakesh Nisar & Co have issued limited review reports with unmodified conclusion on the standalone unaudited financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 The figures for the quarter ended December 31 are the balancing figures between unaudited figures in respect of the nine months ended December 31 and the published year to date unaudited figures for the half year ended September 30 of the respective financial year.
- 5 The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current period.
- 6 The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on February 04, 2025 and were approved and taken on record at the meeting of the Board of Directors of the company held on that date

PLACE: MUMBAI

DATE : 04th February, 2025



FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO
FREDUN N. MEDHORA
DIN : 01745348

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 **Fax:** 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com **Web:** www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

Sr. no	Particulars	Applicability
1	Statement On Deviation Or Variation For Proceeds Of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc.	Not Applicable
2	Format For Disclosing Outstanding Default On Loans And Debt Securities	Not Applicable
3	Format For Disclosure Of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)	Not Applicable For Reporting Quarter
4	Statement On Impact Of Audit Qualifications (For Audit Report With Modified Opinion) Submitted Along With Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)	Not Applicable For Reporting Quarter




Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 **Fax:** 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com **Web:** www.fredungroup.com

**ANNEXURE-I**

Details required under SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

SR.NO.	PARTICULARS	DETAILS
a.	Name of the target entity, details in brief such as size, turnover etc.	Name: Fredun Retail Private Limited Size/Turnover: Not Applicable
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length."	Upon allotment of shares, the new Wholly Owned Subsidiary would be a related party to the Company.
c.	Industry to which the entity being acquired belongs;	Retail Industry
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Expand Retail Chain of the Company.
e.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
f.	Indicative time period for completion of the acquisition;	Not applicable
g.	Consideration - whether cash consideration or share swap or any other form and details of the same;	100% subscription to the share capital in cash.
h.	Cost of acquisition and/or the price at which the shares are acquired;	at face value per share.
i.	Percentage of shareholding / control acquired and / or number of shares acquired;	100%
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not Applicable

